Cargando…
Dual Inhibition of Pirarubicin-Induced AKT and ERK Activations by Phenformin Sensitively Suppresses Bladder Cancer Growth
Activations of Akt or ERK pathway induced by clinical drugs promote therapeutic failure due to decrease of drug response, and no available strategies have been developed to solve these problems. In this study, we found that pirarubicin (THP), one important chemotherapeutic drug for treating bladder...
Autores principales: | Peng, Mei, Deng, Jun, Zhou, Sichun, Xiao, Di, Long, Jiahui, Zhang, Nan, He, Caimei, Mo, Miao, Yang, Xiaoping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791928/ https://www.ncbi.nlm.nih.gov/pubmed/31649535 http://dx.doi.org/10.3389/fphar.2019.01159 |
Ejemplares similares
-
Phenformin alone or combined with gefitinib inhibits bladder cancer via AMPK and EGFR pathways
por: Huang, Yanjun, et al.
Publicado: (2018) -
Phenformin and ataxia‐telangiectasia mutated inhibitors synergistically co‐suppress liver cancer cell growth by damaging mitochondria
por: Wu, Tianyu, et al.
Publicado: (2021) -
In vitro and in vivo studies of pirarubicin-loaded SWNT for the treatment of bladder cancer
por: Chen, Gang, et al.
Publicado: (2012) -
Application of pirarubicin photosensitizer fluorescence cystoscopy in early detection of bladder cancer
por: Jiang, Bo, et al.
Publicado: (2017) -
Schisandrin B Antagonizes Cardiotoxicity Induced by Pirarubicin by Inhibiting Mitochondrial Permeability Transition Pore (mPTP) Opening and Decreasing Cardiomyocyte Apoptosis
por: Shi, Hongwei, et al.
Publicado: (2021)